| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 05/30/2002 | WO2001098482A3 Liver-specific gene expression cassettes, and methods of use |
| 05/30/2002 | WO2001095928A3 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 05/30/2002 | WO2001092565A8 Diagnosis of diseases associated dna transcription by means of assessing the methylation status of genes associated with dna transcription |
| 05/30/2002 | WO2001068888A3 Production of chimeric capsid vectors |
| 05/30/2002 | WO2001066746A3 G-protein coupled receptor related polypeptides |
| 05/30/2002 | WO2000078952A8 Human rna metabolism proteins (rmep) |
| 05/30/2002 | US20020065393 Human hypoxanthine- (guanine) phosphoribosy1 transferase-2 |
| 05/30/2002 | US20020065327 Pharmaceutically active compounds and methods of use thereof |
| 05/30/2002 | US20020065326 Patient oxygenation using stabilized fluorocarbon emulsions |
| 05/30/2002 | US20020065302 Cyclic AMP-specific phosphodiesterase inhibitors |
| 05/30/2002 | US20020065296 Administering heteroarylurea compound for therapy of cytokine mediated diseases and proteolytic enzyme mediated diseases |
| 05/30/2002 | US20020065284 Dipeptide derivatives |
| 05/30/2002 | US20020065277 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 05/30/2002 | US20020065270 For use in therapy of inflammatory diseases such as, for example, rheumatoid arthritis |
| 05/30/2002 | US20020065238 EPO primary response gene, EPRG3pt |
| 05/30/2002 | US20020065220 For use in diagnosis and therapy of disorders treating disorders related to these novel human immunoglobulin-like (Ig- like) proteins |
| 05/30/2002 | US20020064856 Novel proteases |
| 05/30/2002 | US20020064826 Cytokine receptor-like polynucleotides, polypeptides, and antibodies |
| 05/30/2002 | US20020064812 Plasmid for use in the treatment of blood disorders |
| 05/30/2002 | US20020064524 Formulation for topical non-invasive application in vivo |
| 05/30/2002 | CA2430037A1 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 05/30/2002 | CA2429630A1 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 05/30/2002 | CA2429579A1 Truncated cd200 |
| 05/30/2002 | CA2429467A1 Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding |
| 05/30/2002 | CA2429442A1 Aminothiazoles and their use as adenosine receptor antagonists |
| 05/30/2002 | CA2429328A1 Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases |
| 05/30/2002 | CA2429309A1 Novel carbamate-substituted pyrazolopyridine derivatives |
| 05/30/2002 | CA2428191A1 Acid derivatives useful as serine protease inhibitors |
| 05/30/2002 | CA2427444A1 3-arylindole derivatives and their use as cb2 receptor agonists |
| 05/29/2002 | EP1209152A1 Omega-amino-alpha-hydroxycarboxylic acid derivatives having integrin alpha v beta 3 antagonism |
| 05/29/2002 | EP1208384A2 Methods and compositions for modulating oxidized ldl transport |
| 05/29/2002 | EP1208338A1 Methods and apparatus for producing phase change ice particulate saline slurries |
| 05/29/2002 | EP1208235A1 Abc transport polynucleotides, polypeptides, and antibodies |
| 05/29/2002 | EP1208201A2 Compositions and methods for the treatment of immune related diseases |
| 05/29/2002 | EP1208097A2 Substituted oxoazaheterocyclyl compounds |
| 05/29/2002 | EP1208088A2 Fluorene derivatives as integrin inhibitors |
| 05/29/2002 | EP1207891A2 Use of a low molecular weight sulphated polysaccharide to obtain a medicine with antithrombotic activity |
| 05/29/2002 | EP1207880A1 Torsemide polymorphs |
| 05/29/2002 | EP1207879A1 Nicotine receptor agonists in stem cell and progenitor cell recruitment |
| 05/29/2002 | EP1207863A2 New uses for potassium channel openers, such as the treatment of epilepsy |
| 05/29/2002 | EP1207860A1 Controlled release pellet formulation |
| 05/29/2002 | EP1207852A1 Controlled release oral dosage suitable for oral administration |
| 05/29/2002 | EP1061812A4 Food products having enhanced cocoa polyphenol content and processes for producing same |
| 05/29/2002 | CN1351656A Human liver progenitors |
| 05/29/2002 | CN1351614A Human antibodies that bind human IL-12 and methods for producing |
| 05/29/2002 | CN1351609A Low-molecular inhibitors of complement proteases |
| 05/29/2002 | CN1351604A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease |
| 05/29/2002 | CN1351595A Substituted polycyclic aryl and heteroacryl pyrazinones useful for selective inhibition of the coagulation cascade |
| 05/29/2002 | CN1351594A Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents |
| 05/29/2002 | CN1351593A Substituted polycyclic aryl and heteroaryl pyrymidinones useful as anticoagulants agents |
| 05/29/2002 | CN1351592A Acyl derivatives which treat VL4-4 related disorders |
| 05/28/2002 | USRE37721 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| 05/28/2002 | US6395781 Reducing vascular diameter |
| 05/28/2002 | US6395737 Malonic acid derivatives, processes for their preparation, for their use and pharmaceutical compositions containing them |
| 05/28/2002 | US6395731 Anticoagulants |
| 05/28/2002 | US6395707 Methods of treatment utilizing variants of vascular endothelial cell growth factor |
| 05/28/2002 | US6395270 Activated protein C formulations |
| 05/28/2002 | CA2071651C A parenterally administrable drug having thrombolytic activity and containing protein c |
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040540A2 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040475A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040469A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040453A1 Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as ip antagonists |
| 05/23/2002 | WO2002040047A2 Method for treating thrombocytopenia with monoclonal ivig |
| 05/23/2002 | WO2002040039A2 In vivo use of water absorbent polymers |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040016A2 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 05/23/2002 | WO2002040007A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | WO2002039988A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | WO2001092253A3 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 05/23/2002 | WO2001087882A3 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 05/23/2002 | WO2001087284A3 Aldosterone antagonist composition for release during aldosterone acrophase |
| 05/23/2002 | WO2001079444A3 Albumin fusion proteins |
| 05/23/2002 | WO2001074344A3 Small organic molecule regulators of cell proliferation |
| 05/23/2002 | WO2001072708A3 OXINDOLE INHIBITORS OF FACTOR Xa |
| 05/23/2002 | WO2001049304A3 Aqueous ionic solutions and their uses in particular in ophthalmology |
| 05/23/2002 | WO2001047946A9 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 05/23/2002 | WO2000063204A3 Substituted azoles |
| 05/23/2002 | US20020062019 Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation |
| 05/23/2002 | US20020061924 Antiischemic agents, improving deformability of erythrocyte membrane and peripheral circulation |
| 05/23/2002 | US20020061923 Diacid isoindoleine amide derivative |
| 05/23/2002 | US20020061917 Efficient process for the preparation of a factor Xa inhibitor |
| 05/23/2002 | US20020061914 Benzothiazole, benzooxazole and benzoimidazole derivatives as sodium or calcium channel modulators |
| 05/23/2002 | US20020061911 Enantiomers of 6-amino EM-12 and method of use |
| 05/23/2002 | US20020061887 For therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis |
| 05/23/2002 | US20020061872 For oral administration or embedded or otherwise attached to medical devices for blood collection and/or treatment |
| 05/23/2002 | US20020061871 Photochemotherapeutic compositions |
| 05/23/2002 | US20020061863 Consisting of 4-thiouridine, isomaltitol, and uridine; also for problems in hemostasis related to platelet function or inflammation associated with bacterial infection |
| 05/23/2002 | US20020061853 Caspase inhibtors and uses thereof |
| 05/23/2002 | US20020061852 Methods of therapy with thrombin derived peptides |
| 05/23/2002 | US20020061846 Administering to a mammal Group B- beta hemolytic streptococci(GBS) toxin receptors or immunogenic fragments to induce an immune response to the GBS receptors for prventing pathoangiogenic conditions |
| 05/23/2002 | US20020061844 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt |
| 05/23/2002 | US20020061576 Tissue plasminogen activator-like protease |
| 05/23/2002 | DE10057751A1 New carbamate-substituted pyrazolo (3,4-b) pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation |
| 05/23/2002 | DE10057443A1 Use of specific antibodies, or individual chains, for treating tumors and vascular occlusions, by inhibition of the gpIIb/IIIa receptor |
| 05/23/2002 | CA2856033A1 Use of a monoclonal antibody specific for a leukocyte to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |
| 05/23/2002 | CA2763223A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2467781A1 Use of a monoclonal antibody specific for a red blood cell to inhibit the reticuloendothelial system for the treatment of thrombocytopenia |